Vishal Jhanji
The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone.
In this prospective, randomized, parallel-group clinical cohort study, the investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone. The primary objective is to compare the mean 3-month BCVA (logMAR) between the intervention arm (standard topical antibiotic therapy + FML 0.1%) and a control arm (standard topical antibiotic therapy alone).
Inclusion Criteria: 1. Adults aged ≥ 18 years. 2. Clinical diagnosis of a bacterial corneal ulcer based on slit-lamp examination. 3. Ulcer severity classified as: * Mild: Diameter ≤ 3 mm AND stromal depth ≤ 1/3 thickness. * Moderate: Diameter \>3-6 mm and/or stromal depth \> 1/3-2/3. * Severe: Diameter \>6 mm and/or stromal depth \>2/3. 4. Completed microbiologic work-up including ≥ 1 of: * Corneal culture, or * PCR testing. 5. Received ≥ 48-96 hours of empiric topical antibiotic therapy prior to randomization (fluoroquinolone monotherapy or fortified cefazolin/tobramycin bas…
Adjunctive Topical Fluorometholone (FML) 0.1% will be used
Patients will be treated with antibiotics (Cefazolin, Tobramycin or Moxifloxacin) we per treating physician
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.